(Alliance News) - Open Orphan PLC said Monday it has signed five pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform.
The five unnamed companies that signed up to the Genomic Health DataBANK platform will ensure the database is "fit-for-purpose" from a pharmaceutical and data analysis perspective ahead of the first patient data upload.
The platform is expected to be completed and rolled out in the first quarter of 2020, the rare and orphan drug consulting services platform said.
"This builds upon our previously announced collaboration with Empiric Logic who will work with the company to complete the platform," the firm said.
Open Orphan signed an agreement with Empiric Logic in October to finish building its Health Data platform.
"These strategic agreements will allow Open Orphan to deliver on its objective to build Europe's first rare disease, advocacy-led genomic database which will empower patients to directly research into their own respective disease," the company said.
Also, the company said it is working to finalize early adopter agreements with "several patient advocacy groups", who will make their patients aware of Open Orphan's genomic database.
Maurice Treacy, chief commercial officer, said: "We believe that DataBANK can ignite research for new diagnostic tools and therapeutic products for rare disease patients."
Open Orphan shares were up 1.9% in London at 6.37 pence each on Monday.
By Loreta Juodagalvyte; loretajuodagalvyte@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
